Диссертация (1154758), страница 20
Текст из файла (страница 20)
– №365. P. 579-587.115. Einarson, T.R. Principles and practice of pharmacoepidemiology [Text] / T.R.Einarson, U. Bergman, B. Wiholm // In: Speight T.M., Holford N.H.G., editors. Avery’sDrug Treatment. 4th ed. New Zealand: Adis International Limited. - 1997. – P. 371-392.116. Boxtel, C.J. Some observations on pharmacoepidemiology in Europe [Text] / C.J.Boxtel, G. Wang // Nethelands J Med/ – 1997. №51. P. 205-212.117. EuropeanDrugUtilizationResearchGroup.[Available]/.http://www.eurodurg.com118.
ESPGHAN/ESPID Evidence-based Guidelines for the Management of acutegastroenteritis in children in Europe [Text] / A. Guarino, F. Albano, S. Ashkenasi, [etal.]//- J Pediatric Gastroenter Nutr 2008; 46, Suppl. 2:S81-184.119.Guerrant, R.L. A cost effective and effective approach to the diagnosis andmanagement of acute infectious diarrhea [Text] / R. Guerrant, C.A.Wanke, L.J. Barrett //Pediatr Infect Dis.
- 1986 Jul–Aug;5(4) Р. 458– 465.120. Guerrant, R. Practice guidelines for the management of infectious diarrhea [Text]/R. Guerrant, T.Van Gilder, T. Steiner [et al.]// Clin Infect Dis. 2001 Feb 1; №32(3). Р.331351.121. Haltalin, K.C. Comparison of orally absorbable and nonabsorbable antibiotics inshigellosis [Text]/ K.C. Haltalin, J.D. Nelson, L.V. Hinton, H.T.
Kusmiesz// J. Pediatr. –1968. – Vol. 72. - №5. – P. 708 – 720.131122. Hamer, D. Therapy of infection diseases [Text] / D. Hamer // In: Baddour L.,Gorbach S. Therapy of infect. Dis, 2003. 406 р.123. Hartzema, A.G. Pharmacoepidemiology: an introduction [Text] / A.G. Hartzema ,M.S. Porta, Н.Н.Tilson // 3rd ed. Cincinnati: Harvey Whitney Books Company; 1998.124. Herbst, A.L.
Adenocarcinoma of the vagina: association of maternal stilbestroltherapy with tumor appearance in young women [Text] / A.L. Herbst, H. Ulfelder, D.C.Poskanzer // New Engl J M. 1971. – 284. P. 878-881.125. Hoffman, J.A. Failure of cefotaxime therapy in a child with shigellosis [Text] /J.A. Hoffman, K.S. Kim // Pediatr. Infect. Dis. J. – 1996. – Vol. 15. - №2. – P. 175 – 176.126. Hopkins, S. Clinical toleration and safety of azithromycin in adults andchildren[Text] / S. Hopkins// Rev Contemp Pharmacother. – 1994. №5. – Р.3839.127.
Howie, R.L. Reduced azithromycin susceptibility in Shigella sonnei, United States[Text] / R.L. Howie, J.P. Folster, A. Bowen , [et al.].// Microb Drug Resist. - 2010 Dec. №16(4). – Р.245248.128. Improved use of antimicrobials needed to combat drug resistance [El. resurse]Availablefrom:http://id.medscape.com/MedscapeWire/2001/0200/medwire.0220.]/Proceedings of the 30th International Educational and Scientific Symposium of theSociety of Critical Care Medicine, // Feb. 10-14. 2001.
- San Francisco, California, USA.129. Jacobs, R.F. Pharmacokinetics of intravenously administered azithromycin inpediatric patients [Text] / R.F. Jacobs, H.D. Maples, J.V. Aranda, [et al.] // Pediatr InfectDis J. – 2005. № 24 – Р. 3439.130. Jones, R.N. Ceftibuten: a review of antimicrobial activity, spectrum and othermicrobiologic features [Text] /R. N. Jones // Pediatr.
Infect. Dis. J. – 1995. – V14 (7Suppl.). – Р. 77-83.131. Kapadia, N. Acne treated successfully with azithromycin [Text] /N. Kapadia, A.Talib// Int J Dermatol. – 2004. №43. – Р.7667.132132. Kim, S. Review of antimicrobial resistance of Shigella flexneri isolated in Koreaduring 1998 to 2002. [Text] / S. Kim, J. Kim, H. Jang. // Proceedings of the 1 st FEMSCongress; Ljubljana, Slovenia. 2003. Poster P67.133. Khan, W.A.
Azithromycin is equivalent to ciprofloxacin in the treatment ofshigellosis: results of a randomized, blinded, clinical trial [Text] / W.A. Khan// In: The36th International Conference on Antimicribial Agents and Chemotherapy. New Orleans. – 1996. abstr. LM29.134.Khan, W.A. Treatment of shigellosis: V.Comparison of azithromycin andciprofloxacin. A double-blind, randomized,controlled trial [Text] / W.A.
Khan, C. Seas,U. Dhar [et al.] // Ann Intern Med. 1997 May 1;126(9) Р. 697703.135. Kunin, C.M. Resistance to antimicrobial drugs a worldwide calamity [Text] / C.M.Kunin// Ann Intern Med. – 1993. - 118(7). - P. 557-561.136. Kuschner, R.A. Use of azithromycin for the treatment of Campylobacter enteritisin travelers to Thailand, an area where ciprofloxacin resistance is prevalent [Text] / R.A.Kuschner, A.F. Trofa, R.J. Thomas [et al.]// Clin. Infect. Dis. 1995. № 21. P.536541.137. Labro, M.T. Immunomodulation by macrolide antibiotics [Text] / M.T. Labro, H.Abdelghaffar // J.
Chemother. – 2001. – Р.13. – Р.38.138. Langley, J.M. Azithromycin is as effective as and better tolerated thanerythromycin estolate for the treatment of pertussis [Text] / J.M. Langley, S.A.Halperin, F.D. Boucher, [et al.] // Pediatrics. – 2004. – 114. – Р.96101.139. Lalak, N.J. Azithromycin clinical pharmacokinetics [Text] / N.J. Lalak, D.L.Morris // Clin Pharmacokinet. – 1993. –№ 25. Р.370-3744.140. Lee, J.A.H. Prescribing in three English towns. [Text] / J.A.H.
Lee, P.A. Draper,M. Weatherall // Mem Fund Q. – 1965. №43. P. 285-290.141. Ling, J.M. Antimicrobial susceptibilities and β-lactamase production of HongKong isolates of gastroenteric salmonellae and Salmonella typhi [Text] / J.M. Ling,133G.M. Zhou, T.H. Woo// French G.L. J Antimicrob Chemother. 1991. – №22. – Р.111123.142. MacKenzie, F.M. Report of the Consensus Conference on Antibiotic Resistance;Prevention and Control (ARPAC) [Text] / F.M. MacKenzie , M.J.Struelens, K.J.Towner// Clin Microbiol Infect.- 2005. - 11(11). P. 938-954.143. Mates, A. Antimicrobial resistance trends in Shigella serogroups isolated in Israel[Text] / A. Mates, D. Eyny, S.
Philo// Eur J Clin Microbiol Infect Dis. 2000. – №19. –Р.108-111.144. McBride, W.G. Thalidomide and congenital abnormalities [Text] / W.G.McBride// Lancet. – 1961. № 2. P. 1358145. Miron, D. Azithromycin as an alternative to nalidixic acid in the therapy ofchildhood shigellosis [Text] / D. Miron, M. Torem, R. Merom R., [et al.]//The PedInfect Dis J. – 2004. №23(4). Р. 367-8.146. M.H. Drug use review: operational definitions[Text] // Am J Hosp Pharm – 1978.– №35. P. 76-78.147. Nelson, J.D.
Amoxicillin less effective than ampicillin against Shigella in vitro andin vivo: relationship of efficacy to activity in serum [Text] / J.D. Nelson, K.C. Haltalin //J. Infect.Dis. – 1974. – Vol. 129 (Suppl). – P. 222 – 227.148. Paulus, W.E. Pharmacotherapy in pregnancy [Text] // Ther Umsch. – 1999.
56 P.602-607.149. Pharmacokinetics of azithromycin in pediatric patients after oral administration ofmultiple doses of suspension [Text] / Nahata M.C., Koranyi K.I., Gadgil S.D., [etal.]// Antimicrob Agents Chemother. 1993. – №37. – Р.314-316.150.Pharmacokinetics of azithromycin in pediatric patients with acute otitis media[Text] /Nahata M.C., Koranyi K.I., Luke D.R., [et al.]// Antimicrob Agents Chemother.– 1995.
– №39. – Р.1875-1877.151. Pilbeam, M. Antibiotic advice [Text] / M. Pilbeam, K. Harvey // Aust FamPhysician. – 1987. – Vol. 16. – P. 369-370.134152. Oh, J.Y. Changes in patterns of antimicrobial susceptibility and integron carriageamong Shigella sonnei isolates from Southwestern Korea during epidemic periods[Text] /J.Y.
Oh, H.S. Yu, S.K. Kim [el al.]// J Clin Microbiol. – 2003. – 41. – Р. 421-423.153.Macrolide Antibiotics [Text] / Omura S., editor. // Macrolide Antibiotics. 2ndedition. Academic Press. – 2002. №24. Р. 267-8.154. Wise, R., Antimicrobial resistance is a major threat [Text] / R. Wise, T. Hart,O.Cars// public health Br Med J. – 1998. V.317. P.609-610.155. Woo, P.C. Macrolides as immunomodulatory agents [Text] / P.C.Woo, S.K. Lau,K.Y. Yuen // Curr Med Chem –Anti-Inflammatory & Anti-Allergy Agents. – 2002. №1.
P.131-141.156. Pegues, D.A. Salmonella species, including Salmonella typhi[Text] / D.A. PeguesM.E. Ohl, S.I. Miller// In: Mandell GL, Bennett JE, Dolin R: Mandell, Douglas, andBennett’s Principles and practice of infectious diseases. Ed. 6. Philadelphia: ElsevierChurchill Livingstone. 2005. P.2636-54.157.
Periti, P. Pharmacokinetic drug interactions of macrolides [Text] / P. Periti, T.Mazzei, A. Novelli // Clin Pharmacokinet. 1992. №23. P.106-31.158. Prats, G. Antibiotic resistance trends in enteropathogenic bacteria isolated in 19851987 and 1995 1998 in Barcelona [Text] / G.Prats, B. Mirelis [et. al.].
// AntimicrobAgents Chemother. – 2000. – №44. – P.1140-5.159. Prescott, W.A. Antiinflammatory therapies for cystic fibrosis: past, present, andfuture [Text] /W.A. Prescott, C.E. Johnson // Pharmacotherapy. – 2005. – 25. Р.555-73.160. Radice, M. Third generation cephalosporin resistance in Shigella sonnei [Text]/M. Radice, C. Gonzalez, P.
Power [et al].// Argentina Emerg Infect Dis. – 2001. №7. –Р.442-443.161. Robinson, M.J. Fetal warfarin syndrome [Text] / M.J. Robinson, J.Pash, J.Grimwade // Med J Aust. – 1978; V.1. – P. 157.135162. Ruuskanen, O. Safety and tolerability of azithromycin in pediatric infectiousdiseases: 2003 update [Text] / O. Ruuskanen// Pediatr Infect Dis J. – 2004. №23.Р.135-139.163. Salam, M.A.
Treatment of shigellosis: IV Cefixime is ineffective in shigellosis inadults [Text] / M.A. Salam, C. Seas, W.A. Khan, M.L. Bennish // Ann. Intern. Med. –1995. – Vol. 123. - №7. – P. 505 – 508.164. Siegel, J.D. Healthcare Infection Control Practices Advisory Committee.Management of multidrugresistant organisms in healthcare settings [El. resurse] / J.D.Siegel,E.Rhinehart,M.Jackson//Availablefrom:http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf.165. Shitrit, D. Longterm azithromycin use for treatment of bronchiolitis obliteranssyndrome in lung transplant recipients [Text] / D. Shitrit, D.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
